Compare The Vita Coco Company Inc (COCO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Vita Coco Company Inc vs ResMed Inc. — how do they compare? The Vita Coco Company Inc trades at $65.15 (market cap $3.73B), while ResMed Inc. trades at $223.61 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 8.7× The Vita Coco Company Inc's market cap, and ResMed Inc. pays a 1.17% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| COCO | RMD | |
|---|---|---|
Market Cap | $3.73B | $32.61B |
Sector | Technology | Health |
52-Week High | $84.02 | $293.73 |
52-Week Low | $32.37 | $182.82 |
Enterprise Value | $3.47B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COCO trades at $64.96, up 3.47% on the day, with strong earnings beats in Q1 and Q2 2026 driving momentum. The stock shows a bearish technical signal but bullish oscillators, with support near $62 and resistance at $65. Recent Q2 results featured 28% revenue growth and raised 2026 guidance, supported by the Copra acquisition and international expansion.
Outlook is positive with 60% analyst buy ratings and an $80.67 price target, though high valuation multiples and cost pressures pose risks. Growth catalysts include brand demand and market share gains, while investor sentiment is bolstered by defensive stock attributes amid economic uncertainty.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
